Irish company Covidien has launched ReliaTack, a new articulating reloadable fixation device for laparoscopic or minimally invasive hernia repair.
ReliaTack is claimed to be the first and only such device available for laparoscopic hernia repair and it provides superior access, stronger fixation and lower cost of care.
Go deeper with GlobalData
The new device features a 65-degree articulation and is equipped with screw-like tacks, providing double the strength of other fixation devices available in the market, and come in interchangeable five and ten-tack reload sets.
Covidien vice-president Rob Claypoole said: “Developed with valuable input from surgeons, the ReliaTack device, combined with our recently-launched Symbotex composite mesh benefits patients, while helping drive greater operating room efficiency and economic benefits.
“The ReliaTack fixation device overcomes numerous physical and ergonomic challenges in ventral hernia repair by allowing a wide variety of angles to more effectively position and secure hernia mesh.”
Compared to the ReliaTack device, using a non-articulating model can make it more difficult accessing mesh fixation sites, less fixation strength, and an increase in cost when more than one device must be used in a single procedure.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCovidien research and development vice-president Matt Cohen said: “Covidien’s proven tack design helps surgeons ensure that the mesh will stay in place, one of the key concerns of hernia repair surgery.
“By offering interchangeable tack reload sets, ReliaTack helps to eliminate much of the waste associated with non-articulating devices.”
In April, US Food and Drug Administration granted 510(K) clearance for the ReliaTack device.
More than 90,000 ventral hernia repair procedures are expected to be conducted in the US each year, according to the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).
Image: ReliaTack from Covidien is the first and only articulating reloadable absorbable fixation device for minimally-invasive ventral hernia repair. Photo: courtesy of Covidien /Business Wire.
